Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304548 · ClinicalTrials.gov registry record
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 10
- Enrollment target
NCT03304548: Completed study, sponsored by GlaxoSmithKline.
NCT03304548 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03304548 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualitative interview study with PAH subjects to explore subject's perspective and preferences for various modes of treatment administration (daily or weekly subcutaneous injection versus current treatment options). This will be a qualitative study comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to 10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).
Primary Outcome
All recruited subjects will take part in a 30-minute telephone interview. Subjects will be given brief descriptions of hypothetical injection and inhaled treatments and will be asked for their thoughts towards these treatments individually.
Interventions
- OTHER Telephone concept elicitation interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2018-04-10 |
What the finished NCT03304548 record still lists
NCT03304548 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Telephone concept elicitation interview is the first listed.
NCT03304548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03304548 about?
NCT03304548 is a clinical study titled "Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects". GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualit...
What is the current status of trial NCT03304548?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2017-11-22. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT03304548?
The interventions under investigation include: Telephone concept elicitation interview (OTHER).
Who is sponsoring clinical trial NCT03304548?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI